List of Publications by Year in descending order

135 papers	4,151 citations	87843 38 h-index	175177 52 g-index
136 all docs	136 docs citations	136 times ranked	5254 citing authors

#	Article	IF	Citations
1	Myxobacterial depsipeptide chondramides interrupt SARS-CoV-2 entry by targeting its broad, cell tropic spike protein. Journal of Biomolecular Structure and Dynamics, 2022, 40, 12209-12220.	2.0	10
2	Virtual Combinatorial Library Screening of Quinadoline B Derivatives against SARS-CoV-2 RNA-Dependent RNA Polymerase. Computation, 2022, 10, 7.	1.0	12
3	Polypharmacological Approaches for CNS Diseases: Focus on Endocannabinoid Degradation Inhibition. Cells, 2022, 11, 471.	1.8	21
4	Total Synthesis of the Natural Chalcone Lophirone E, Synthetic Studies toward Benzofuran and Indole-Based Analogues, and Investigation of Anti-Leishmanial Activity. Molecules, 2022, 27, 463.	1.7	10
5	Design and Synthesis of New Oligopeptidic Parvulin Inhibitors. ChemMedChem, 2022, , .	1.6	3
6	Design and synthesis of multifunctional microtubule targeting agents endowed with dual pro-apoptotic and anti-autophagic efficacy. European Journal of Medicinal Chemistry, 2022, 235, 114274.	2.6	6
7	In Silico Analysis of Peptide-Based Derivatives Containing Bifunctional Warheads Engaging Prime and Non-Prime Subsites to Covalent Binding SARS-CoV-2 Main Protease (Mpro). Computation, 2022, 10, 69.	1.0	3
8	Azetidin-2-one-based small molecules as dual hHDAC6/HDAC8 inhibitors: Investigation of their mechanism of action and impact of dual inhibition profile on cell viability. European Journal of Medicinal Chemistry, 2022, 238, 114409.	2.6	11
9	Structure-activity relationships study of isothiocyanates for H2S releasing properties: 3-Pyridyl-isothiocyanate as a new promising cardioprotective agent. Journal of Advanced Research, 2021, 27, 41-53.	4.4	28
10	Novel quinolone-based potent and selective HDAC6 inhibitors: Synthesis, molecular modeling studies and biological investigation. European Journal of Medicinal Chemistry, 2021, 212, 112998.	2.6	22
11	Selective Fatty Acid Amide Hydrolase Inhibitors as Potential Novel Antiepileptic Agents. ACS Chemical Neuroscience, 2021, 12, 1716-1736.	1.7	12
12	Harnessing the Role of HDAC6 in Idiopathic Pulmonary Fibrosis: Design, Synthesis, Structural Analysis, and Biological Evaluation of Potent Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 9960-9988.	2.9	26
13	In silico analysis of RNA-dependent RNA polymerase of the SARS-CoV-2 and therapeutic potential of existing antiviral drugs. Computers in Biology and Medicine, 2021, 135, 104591.	3.9	9
14	Identification of novel SIRT1 activators endowed with cardioprotective profile. European Journal of Pharmaceutical Sciences, 2021, 165, 105930.	1.9	5
15	Discovery of novel hit compounds as potential HDAC1 inhibitors: The case of ligand- and structure-based virtual screening. Computers in Biology and Medicine, 2021, 137, 104808.	3.9	22
16	Artificial Intelligence in Translational Medicine. International Journal of Translational Medicine, 2021, 1, 223-285.	0.1	2
17	Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases. Journal of Medicinal Chemistry, 2020, 63, 23-39.	2.9	69
18	Screening and Phenotypical Characterization of Schistosoma mansoni Histone Deacetylase 8 (SmHDAC8) Inhibitors as Multistage Antischistosomal Agents. ACS Infectious Diseases, 2020, 6, 100-113.	1.8	26

#	Article	IF	Citations
19	Organic Isothiocyanates as Hydrogen Sulfide Donors. Antioxidants and Redox Signaling, 2020, 32, 110-144.	2.5	51
20	Spiroindoline-Capped Selective HDAC6 Inhibitors: Design, Synthesis, Structural Analysis, and Biological Evaluation. ACS Medicinal Chemistry Letters, 2020, 11, 2268-2276.	1.3	23
21	Structure-Based Design of Biologically Active Compounds. Molecules, 2020, 25, 3115.	1.7	3
22	Development of In Vitro Corneal Models: Opportunity for Pharmacological Testing. Methods and Protocols, 2020, 3, 74.	0.9	5
23	Cinnamides Target Leishmania amazonensis Arginase Selectively. Molecules, 2020, 25, 5271.	1.7	15
24	MicroRNA-Based Multitarget Approach for Alzheimerâ€™s Disease: Discovery of the First-In-Class Dual Inhibitor of Acetylcholinesterase and MicroRNA-15b Biogenesis. Journal of Medicinal Chemistry, 2020, 63, 9695-9704.	2.9	17
25	Amyloid Î² fibril disruption by oleuropein aglycone: long-time molecular dynamics simulation to gain insight into the mechanism of action of this polyphenol from extra virgin olive oil. Food and Function, 2020, 11, 8122-8132.	2.1	21
26	Modulation of the Innate Immune Response by Targeting Toll-like Receptors: A Perspective on Their Agonists and Antagonists. Journal of Medicinal Chemistry, 2020, 63, 13466-13513.	2.9	75
27	Design, synthesis and biological evaluation of 7-substituted 4-phenyl-6H-imidazo[1,5-a]thieno[3,2-f][1,4]diazepines as safe anxiolytic agents. European Journal of Medicinal Chemistry, 2020, 200, 112405.	2.6	4
28	Ionotropic Glutamate Receptor GluA2 in Complex with Bicyclic Pyrimidinedione-Based Compounds: When Small Compound Modifications Have Distinct Effects on Binding Interactions. ACS Chemical Neuroscience, 2020, 11, 1791-1800.	1.7	8
29	Retinitis Pigmentosa and Retinal Degenerations: Deciphering Pathways and Targets for Drug Discovery and Development. ACS Chemical Neuroscience, 2020, 11, 2173-2191.	1.7	10
30	The Citrus Flavonoid Naringenin Protects the Myocardium from Ageing-Dependent Dysfunction: Potential Role of SIRT1. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-15.	1.9	52
31	Computer-Driven Development of an in Silico Tool for Finding Selective Histone Deacetylase 1 Inhibitors. Molecules, 2020, 25, 1952.	1.7	15
32	Telomerase-based Cancer Therapeutics: A Review on their Clinical Trials. Current Topics in Medicinal Chemistry, 2020, 20, 433-457.	1.0	33
33	Identification of Novel 3-Hydroxy-pyran-4-One Derivatives as Potent HIV-1 Integrase Inhibitors Using in silico Structure-Based Combinatorial Library Design Approach. Frontiers in Chemistry, 2019, 7, 574.	1.8	32
34	Computational Approaches for Drug Discovery. Molecules, 2019, 24, 3061.	1.7	36
35	An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction. Computational Biology and Chemistry, 2019, 83, 107105.	1.1	42
36	Dealing with schistosomiasis: Current drug discovery strategies. Annual Reports in Medicinal Chemistry, 2019, 53, 107-138.	0.5	10

#	Article	IF	Citations
37	Synthesis, biological evaluation and molecular modeling of novel selective COX-2 inhibitors: sulfide, sulfoxide, and sulfone derivatives of 1,5-diarylpyrrol-3-substituted scaffold. Bioorganic and Medicinal Chemistry, 2019, 27, 115045.	1.4	21
38	Development of novel multipotent compounds modulating endocannabinoid and dopaminergic systems. European Journal of Medicinal Chemistry, 2019, 183, 111674.	2.6	14
39	Allosteric Modulation of Ionotropic Glutamate Receptors: An Outlook on New Therapeutic Approaches To Treat Central Nervous System Disorders. ACS Medicinal Chemistry Letters, 2019, 10, 228-236.	1.3	27
40	Bridged bicyclic 2,3-dioxabicyclo[3.3.1]nonanes as antiplasmodial agents: Synthesis, structure-activity relationships and studies on their biomimetic reaction with Fe(II). Bioorganic Chemistry, 2019, 89, 103020.	2.0	13
41	Dietary polyphenols rutin, taxifolin and quercetin related compounds target Leishmania amazonensis arginase. Food and Function, 2019, 10, 3172-3180.	2.1	32
42	A light in the dark: state of the art and perspectives in optogenetics and optopharmacology for restoring vision. Future Medicinal Chemistry, 2019, 11, 463-487.	1.1	7
43	A Repurposing Approach for Uncovering the Anti-Tubercular Activity of FDA-Approved Drugs with Potential Multi-Targeting Profiles. Molecules, 2019, 24, 4373.	1.7	34
44	Cinnamic acids derived compounds with antileishmanial activity target Leishmania amazonensis arginase. Chemical Biology and Drug Design, 2019, 93, 139-146.	1.5	20
45	Structure-activity relationships, biological evaluation and structural studies of novel pyrrolonaphthoxazepines as antitumor agents. European Journal of Medicinal Chemistry, 2019, 162, 290-320.	2.6	31
46	Synthesis, Molecular Modelling and Biological Studies of 3-hydroxypyrane- 4-one and 3-hydroxy-pyridine-4-one Derivatives as HIV-1 Integrase Inhibitors. Medicinal Chemistry, 2019, 15, 755-770.	0.7	22
47	Antimalarial agents against both sexual and asexual parasites stages: structure-activity relationships and biological studies of the Malaria Box compound 1-[5-(4-bromo-2-chlorophenyl)furan-2-yl]-N-[(piperidin-4-yl)methyl]methanamine (MMV019918) and analogues. European Journal of Medicinal Chemistry, 2018, 150, 698-718.	2.6	27
48	(S)-2-Amino-3-(5-methyl-3-hydroxyisoxazol-4-yl)propanoic Acid (AMPA) and Kainate Receptor Ligands: Further Exploration of Bioisosteric Replacements and Structural and Biological Investigation. Journal of Medicinal Chemistry, 2018, 61, 2124-2130.	2.9	20
49	Development of Potent Inhibitors of the Mycobacterium tuberculosis Virulence Factor Zmp1 and Evaluation of Their Effect on Mycobacterial Survival inside Macrophages. ChemMedChem, 2018, 13, 422-430.	1.6	43
50	A Jocic-type approach for a practical and scalable synthesis of pyrrolonaphthoxazepine (PNOX)-based potent proapoptotic agents. Tetrahedron Letters, 2018, 59, 4466-4470.	0.7	5
51	Synthetic studies toward bicyclic endoperoxides presenting polar side chains. Tetrahedron Letters, 2018, 59, 4330-4333.	0.7	1
52	Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies. European Journal of Medicinal Chemistry, 2018, 157, 127-138.	2.6	39
53	Development of Potent Inhibitors of Fatty Acid Amide Hydrolase Useful for the Treatment of Neuropathic Pain. ChemMedChem, 2018, 13, 2090-2103.	1.6	19
54	iPSC-derived neurons profiling reveals GABAergic circuit disruption and acetylated Î±-tubulin defect which improves after iHDAC6 treatment in Rett syndrome. Experimental Cell Research, 2018, 368, 225-235.	1.2	36

#	Article	IF	Citations
55	Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease. Progress in Neurobiology, 2017, 151, 4-34.	2.8	128
56	Structural characterization of Giardia duodenalis thioredoxin reductase (g TrxR) and computational analysis of its interaction with NBDHEX. European Journal of Medicinal Chemistry, 2017, 135, 479-490.	2.6	35
57	First dual AK/GSK-3Î² inhibitors endowed with antioxidant properties as multifunctional, potential neuroprotective agents. European Journal of Medicinal Chemistry, 2017, 138, 438-457.	2.6	33
58	Synthesis and biological evaluation of a new class of benzothiazines as neuroprotective agents. European Journal of Medicinal Chemistry, 2017, 126, 614-630.	2.6	14
59	Activation of the Wnt Pathway by Small Peptides: Rational Design, Synthesis and Biological Evaluation. ChemMedChem, 2017, 12, 2074-2085.	1.6	13
60	Identification of novel fluorescent probes preventing PrP Sc replication in prion diseases. European Journal of Medicinal Chemistry, 2017, 127, 859-873.	2.6	39
61	Computational Tool for Fast in silico Evaluation of hERG K+ Channel Affinity. Frontiers in Chemistry, 2017, 5, 7.	1.8	52
62	Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases. Frontiers in Neuroscience, 2016, 10, 451.	1.4	66
63	Development of novel cyclic peptides as pro-apoptotic agents. European Journal of Medicinal Chemistry, 2016, 117, 301-320.	2.6	26
64	Targeting clinically-relevant metallo-Î²-lactamases: from high-throughput docking to broad-spectrum inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 98-109.	2.5	19
65	Verbascoside Inhibits Promastigote Growth and Arginase Activity of Leishmania amazonensis. Journal of Natural Products, 2016, 79, 1459-1463.	1.5	47
66	Phenylpyrrole-based HDAC inhibitors: synthesis, molecular modeling and biological studies. Future Medicinal Chemistry, 2016, 8, 1573-1587.	1.1	19
67	In silico study of subtilisin-like protease 1 (SUB1) from different Plasmodium species in complex with peptidyl-difluorostatones and characterization of potent pan-SUB1 inhibitors. Journal of Molecular Graphics and Modelling, 2016, 64, 121-130.	1.3	17
68	Development of a practical and scalable route for the preparation of the deacetoxytubuvaline (dTuv) fragment of pretubulysin and analogs. Tetrahedron Letters, 2016, 57, 920-923.	0.7	5
69	Development and Pharmacological Characterization of Selective Blockers of 2-Arachidonoyl Glycerol Degradation with Efficacy in Rodent Models of Multiple Sclerosis and Pain. Journal of Medicinal Chemistry, 2016, 59, 2612-2632.	2.9	70
70	Synthesis and biological evaluation of fluorinated 1,5-diarylpyrrole-3-alkoxyethyl ether derivatives as selective COX-2 inhibitors endowed with anti-inflammatory activity. European Journal of Medicinal Chemistry, 2016, 109, 99-106.	2.6	27
71	Donepezil-like multifunctional agents: Design, synthesis, molecular modeling and biological evaluation. European Journal of Medicinal Chemistry, 2016, 121, 864-879.	2.6	80
72	Harnessing the pyrroloquinoxaline scaffold for FAAH and MAGL interaction: definition of the structural determinants for enzyme inhibition. RSC Advances, 2016, 6, 64651-64664.	1.7	19

#	Article	IF	Citations
73	Discovery and Cardioprotective Effects of the First Non-Peptide Agonists of the G Protein-Coupled Prokineticin Receptor-1. PLoS ONE, 2015, 10, e0121027.	1.1	50
74	Plasmodium falciparum subtilisin-like protease 1: discovery of potent difluorostatone-based inhibitors. RSC Advances, 2015, 5, 22431-22448.	1.7	15
75	Structure-based discovery of the first non-covalent inhibitors of Leishmania major tryparedoxin peroxidase by high throughput docking. Scientific Reports, 2015, 5, 9705.	1.6	58
76	Exploring clotrimazole-based pharmacophore: 3D-QSAR studies and synthesis of novel antiplasmodial agents. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 5412-5418.	1.0	15
77	Synthetic spirocyclic endoperoxides: new antimalarial scaffolds. MedChemComm, 2015, 6, 357-362.	3.5	39
78	Development of HuperTacrines as Non-Toxic, Cholinesterase Inhibitors for the Potential Treatment of Alzheimerâ€™s Disease. Mini-Reviews in Medicinal Chemistry, 2015, 15, 648-658.	1.1	12
79	Discovery of GPCR ligands for probing signal transduction pathways. Frontiers in Pharmacology, 2014, 5, 255.	1.6	31
80	From (+)-epigallocatechin gallate to a simplified synthetic analogue as a cytoadherence inhibitor for P. falciparum. RSC Advances, 2014, 4, 4769-4781.	1.7	13
81	Targeting Dopamine D3 and Serotonin 5-HT1A and 5-HT2A Receptors for Developing Effective Antipsychotics: Synthesis, Biological Characterization, and Behavioral Studies. Journal of Medicinal Chemistry, 2014, 57, 9578-9597.	2.9	46
82	Diseaseâ€Modifying Antiâ€Alzheimer's Drugs: Inhibitors of Human Cholinesterases Interfering with Î²â€Amyloid Aggregation. CNS Neuroscience and Therapeutics, 2014, 20, 624-632.	1.9	51
83	Rational design of the first difluorostatone-based PfSUB1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3582-3586.	1.0	38
84	HCV-targeted Antivirals: Current Status and Future Challenges. Current Pharmaceutical Design, 2014, 20, 3445-3464.	0.9	8
85	A stereoselective route to 6-substituted pyrrolo-1,5-benzoxazepinones and their analogues. Tetrahedron Letters, 2013, 54, 5387-5390.	0.7	11
86	Multifunctional Cholinesterase and Amyloid Beta Fibrillization Modulators. Synthesis and Biological Investigation. ACS Medicinal Chemistry Letters, 2013, 4, 1178-1182.	1.3	40
87	A stereoselective approach to peptidomimetic BACE1 inhibitors. European Journal of Medicinal Chemistry, 2013, 70, 233-247.	2.6	17
88	Novel peptidomimetics as BACE-1 inhibitors: Synthesis, molecular modeling, and biological studies. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 85-89.	1.0	15
89	A synthetic strategy to bridged 2,3,8-trioxabicyclo[3,3,1]nonane endoperoxides. Tetrahedron Letters, 2013, 54, 1233-1235.	0.7	10
90	Identification of a novel arylpiperazine scaffold for fatty acid amide hydrolase inhibition with improved drug disposition properties. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 492-495.	1.0	15

#	Article	IF	Citations
91	Synthesis and structureâ€“activity relationship studies in serotonin 5-HT1A receptor agonists based on fused pyrrolidone scaffolds. European Journal of Medicinal Chemistry, 2013, 63, 85-94.	2.6	28
92	Novel Analgesic/Anti-Inflammatory Agents: 1,5-Diarylpyrrole Nitrooxyalkyl Ethers and Related Compounds as Cyclooxygenase-2 Inhibiting Nitric Oxide Donors. Journal of Medicinal Chemistry, 2013, 56, 3191-3206.	2.9	43
93	3D-QSAR using pharmacophore-based alignment and virtual screening for discovery of novel MCF-7 cell line inhibitors. European Journal of Medicinal Chemistry, 2013, 67, 344-351.	2.6	28
94	The Structural Evolution of β-Secretase Inhibitors: A Focus on the Development of Small-Molecule Inhibitors. Current Topics in Medicinal Chemistry, 2013, 13, 1787-1807.	1.0	39
95	Characterization of COR627 and COR628, Two Novel Positive Allosteric Modulators of the GABA_B Receptor. Journal of Pharmacology and Experimental Therapeutics, 2012, 340, 529-538.	1.3	38
96	Mimicking the Intramolecular Hydrogen Bond: Synthesis, Biological Evaluation, and Molecular Modeling of Benzoxazines and Quinazolines as Potential Antimalarial Agents. Journal of Medicinal Chemistry, 2012, 55, 10387-10404.	2.9	58
97	Quinolylhydrazones as novel inhibitors of Plasmodium falciparum serine protease PfSUB1. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 5317-5321.	1.0	28
98	Discovery of Potent Inhibitors of Human and Mouse Fatty Acid Amide Hydrolases. Journal of Medicinal Chemistry, 2012, 55, 6898-6915.	2.9	32
99	Design, Synthesis, and Pharmacological Characterization of Indol-3-ylacetamides, Indol-3-yloxoacetamides, and Indol-3-ylcarboxamides: Potent and Selective CB2 Cannabinoid Receptor Inverse Agonists. Journal of Medicinal Chemistry, 2012, 55, 5391-5402.	2.9	27
100	Optimization of 4-Aminoquinoline/Clotrimazole-Based Hybrid Antimalarials: Further Structureâ€“Activity Relationships, in Vivo Studies, and Preliminary Toxicity Profiling. Journal of Medicinal Chemistry, 2012, 55, 6948-6967.	2.9	43
101	Pyrroloquinoxaline hydrazones as fluorescent probes for amyloid fibrils. Organic and Biomolecular Chemistry, 2011, 9, 5137.	1.5	44
102	Non-Nucleoside Inhibitors of Human Adenosine Kinase: Synthesis, Molecular Modeling, and Biological Studies. Journal of Medicinal Chemistry, 2011, 54, 1401-1420.	2.9	27
103	Selective Kainate Receptor (GluK1) Ligands Structurally Based upon 1H-Cyclopentapyrimidin-2,4(1H,3H)-dione: Synthesis, Molecular Modeling, and Pharmacological and Biostructural Characterization. Journal of Medicinal Chemistry, 2011, 54, 4793-4805.	2.9	21
104	Synthesis and Antiplasmodial Activity of Bicyclic Dioxanes as Simplified Dihydroplakortin Analogues. Journal of Medicinal Chemistry, 2011, 54, 5949-5953.	2.9	25
105	Broad inhibition of plasmodium falciparum cytoadherence by (+)-epigallocatechin gallate. Malaria Journal, 2011, 10, 348.	0.8	11
106	Enantioselective binding of second generation pyrrolobenzoxazepinones to the catalytic ternary complex of HIV-1 RT wild-type and L100I and K103N drug resistant mutants. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 3935-3938.	1.0	4
107	Three-dimensional quantitative structureâ€“selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2. European Journal of Medicinal Chemistry, 2011, 46, 547-555.	2.6	31
108	Discovery of Bishomo(hetero)arylpiperazines as Novel Multifunctional Ligands Targeting Dopamine D3and Serotonin 5-HT1Aand 5-HT2AReceptors. Journal of Medicinal Chemistry, 2010, 53, 4803-4807.	2.9	25

#	Article	IF	Citations
109	Malaria Chemotherapy: Recent Advances in Drug Development. Recent Patents on Anti-infective Drug Discovery, 2010, 5, 195-225.	0.5	13
110	Synthesis of Dihydroplakortin, 6-epi-Dihydroplakortin, and Their C10-Desethyl Analogues. Journal of Organic Chemistry, 2010, 75, 2333-2340.	1.7	42
111	Synthetic studies toward 1,2-dioxanes as precursors of potential endoperoxide-containing antimalarials. Tetrahedron Letters, 2009, 50, 5719-5722.	0.7	24
112	Development of antitubercular compounds based on a 4-quinolylhydrazone scaffold. Further structureâ€“activity relationship studies. Bioorganic and Medicinal Chemistry, 2009, 17, 6063-6072.	1.4	50
113	Discovery of a New Class of Potential Multifunctional Atypical Antipsychotic Agents Targeting Dopamine D3 and Serotonin 5-HT1A and 5-HT2A Receptors: Design, Synthesis, and Effects on Behavior. Journal of Medicinal Chemistry, 2009, 52, 151-169.	2.9	79
114	Novel, Potent, and Selective Quinoxaline-Based 5-HT₃ Receptor Ligands. 1. Further Structureâ^'Activity Relationships and Pharmacological Characterization. Journal of Medicinal Chemistry, 2009, 52, 6946-6950.	2.9	35
115	Combining 4-Aminoquinoline- and Clotrimazole-Based Pharmacophores toward Innovative and Potent Hybrid Antimalarials. Journal of Medicinal Chemistry, 2009, 52, 502-513.	2.9	55
116	Specific Targeting of Highly Conserved Residues in the HIV-1 Reverse Transcriptase Primer Grip Region. 2. Stereoselective Interaction to Overcome the Effects of Drug Resistant Mutations. Journal of Medicinal Chemistry, 2009, 52, 1224-1228.	2.9	15
117	Specific Targeting of Peripheral Serotonin 5-HT₃Receptors. Synthesis, Biological Investigation, and Structureâ^'Activity Relationships. Journal of Medicinal Chemistry, 2009, 52, 3548-3562.	2.9	38
118	Pharmacophore Modeling for Qualitative Prediction of Antiestrogenic Activity. Journal of Chemical Information and Modeling, 2009, 49, 2489-2497.	2.5	30
119	Microwave-assisted synthesis of 4-quinolylhydrazines followed by nickel boride reduction: a convenient approach to 4-aminoquinolines and derivatives. Tetrahedron Letters, 2008, 49, 2074-2077.	0.7	20
120	Tacrine based human cholinesterase inhibitors: Synthesis of peptidic-tethered derivatives and their effect on potency and selectivity. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5213-5216.	1.0	26
121	Selective targeting of the HIV-1 reverse transcriptase catalytic complex through interaction with the â€œprimer gripâ€•region by pyrrolobenzoxazepinone non-nucleoside inhibitors correlates with increased activity towards drug-resistant mutants. Biochemical Pharmacology, 2008, 76, 156-168.	2.0	6
122	Exploiting Protein Fluctuations at the Active-Site Gorge of Human Cholinesterases: Further Optimization of the Design Strategy to Develop Extremely Potent Inhibitors. Journal of Medicinal Chemistry, 2008, 51, 3154-3170.	2.9	56
123	An Efficient Approach to Chiral C8/C9-Piperazino-Substituted 1,4-Benzodiazepin-2-ones as Peptidomimetic Scaffolds. Journal of Organic Chemistry, 2008, 73, 8458-8468.	1.7	27
124	Design, Synthesis, and Structureâ€“Activity Relationship Studies of 4-Quinolinyl- and 9-Acrydinylhydrazones as Potent Antimalarial Agents. Journal of Medicinal Chemistry, 2008, 51, 1333-1343.	2.9	73
125	1H-Cyclopentapyrimidine-2,4(1H,3H)-dione-Related Ionotropic Glutamate Receptors Ligands. Structureâ^'Activity Relationships and Identification of Potent and Selective iGluR5 Modulators. Journal of Medicinal Chemistry, 2008, 51, 6614-6618.	2.9	22
126	Clotrimazole Scaffold as an Innovative Pharmacophore Towards Potent Antimalarial Agents: Design, Synthesis, and Biological and Structureâ€“Activity Relationship Studies. Journal of Medicinal Chemistry, 2008, 51, 1278-1294.	2.9	45

#	Article	IF	Citations
127	Development of piperazine-tethered heterodimers as potent antimalarials against chloroquine-resistant P. falciparum strains. Synthesis and molecular modeling. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 3535-3539.	1.0	18
128	Design and Synthesis of Potent Antimalarial Agents Based on Clotrimazole Scaffold:Â Exploring an Innovative Pharmacophore. Journal of Medicinal Chemistry, 2007, 50, 595-598.	2.9	40
129	Synthesis of N1-arylidene-N2-quinolyl- and N2-acrydinylhydrazones as potent antimalarial agents active against CQ-resistant P. falciparum strains. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 5384-5388.	1.0	142
130	Pyrrolo[1,5]benzoxa(thia)zepines as a New Class of Potent Apoptotic Agents. Biological Studies and Identification of an Intracellular Location of Their Drug Target. Journal of Medicinal Chemistry, 2005, 48, 4367-4377.	2.9	53
131	Development of Molecular Probes for the Identification of Extra Interaction Sites in the Mid-Gorge and Peripheral Sites of Butyrylcholinesterase (BuChE). Rational Design of Novel, Selective, and Highly Potent BuChE Inhibitorsâ€. Journal of Medicinal Chemistry, 2005, 48, 1919-1929.	2.9	65
132	Specific Targeting Highly Conserved Residues in the HIV-1 Reverse Transcriptase Primer Grip Region. Design, Synthesis, and Biological Evaluation of Novel, Potent, and Broad Spectrum NNRTIs with Antiviral Activity. Journal of Medicinal Chemistry, 2005, 48, 7153-7165.	2.9	43
133	Synthesis and Pharmacological Evaluation of Potent and Highly Selective D3 Receptor Ligands:â€‰ Inhibition of Cocaine-Seeking Behavior and the Role of Dopamine D3/D2 Receptors. Journal of Medicinal Chemistry, 2003, 46, 3822-3839.	2.9	90
134	Pyrrolo[1,3]benzothiazepine-Based Atypical Antipsychotic Agents. Synthesis, Structureâ^'Activity Relationship, Molecular Modeling, and Biological Studies. Journal of Medicinal Chemistry, 2002, 45, 344-359.	2.9	36
135	Pyrroloquinoxaline Derivatives as High-Affinity and Selective 5-HT3Receptor Agonists:Â Synthesis, Further Structureâ^'Activity Relationships, and Biological Studies. Journal of Medicinal Chemistry, 1999, 42, 4362-4379.	2.9	103